2013 May Still Be A Trough Year For Bristol As New Drugs Continue To Take Hold
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol remains plagued by the loss of exclusivity for Plavix and setbacks in 2012, but the company hopes to paint a picture of growth as newly approved drugs begin to fill the revenue gap.